|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.14 USD | -5.30% |
|
-1.99% | -21.67% |
| 09/07 | IRenix Medical, Inc., Tarsus Pharmaceuticals, Inc. - M&A Call | |
| 09/07 | Tarsus Pharmaceuticals Buys iRenix Medical | MT |
| Market Cap | 275.96Cr 241.41Cr 222.62Cr 205.98Cr 390.95Cr 26TCr 397.49Cr 2.67TCr 1.05TCr 13TCr 1.04TCr 1.01TCr 45TCr | P/E 2026 * |
-77.6x | P/E 2027 * | 21x |
|---|---|---|---|---|---|
| Enterprise Value | 275.96Cr 241.41Cr 222.62Cr 205.98Cr 390.95Cr 26TCr 397.49Cr 2.67TCr 1.05TCr 13TCr 1.04TCr 1.01TCr 45TCr | EV / Sales 2026 * |
3.96x | EV / Sales 2027 * | 3.04x |
| Free-Float |
96.94% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Tarsus Pharmaceuticals, Inc.
| 1 day | -5.30% | ||
| 1 week | -1.99% | ||
| Current month | +1.91% | ||
| 1 month | +4.21% | ||
| 3 months | -11.44% | ||
| 6 months | -16.56% | ||
| Current year | -21.67% |
| 1 week | 61.71 |  | 72.5 |
| 1 month | 56.51 | | 72.5 |
| Current year | 56 | | 83.92 |
| 1 year | 38.51 | | 85.25 |
| 3 years | 12.57 | | 85.25 |
| 5 years | 10.8 | | 85.25 |
| 10 years | 10.8 | | 85.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Bobak Azamian
CEO | Chief Executive Officer | 48 | 01/09/2018 |
Jeffrey Farrow
DFI | Director of Finance/CFO | 64 | 24/04/2023 |
| Chief Tech/Sci/R&D Officer | 47 | 04/11/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Bobak Azamian
CHM | Chairman | 48 | 02/12/2022 |
| Director/Board Member | 71 | 01/12/2019 | |
Bill Link
BRD | Director/Board Member | 80 | 01/01/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 25/06 | Free | Director | 6,254 | 0.0145% | ||
| 25/06 | Free | Director | 6,254 | 0.0145% | ||
| 25/06 | Free | Director | 7,463 | 0.0173% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.30% | -1.99% | +55.34% | +264.22% | 275.96Cr | |
| +0.76% | +2.09% | +20.88% | -3.54% | 6.8TCr | |
| +0.92% | -2.77% | +46.18% | +221.65% | 5.44TCr | |
| -2.79% | +32.50% | +32.50% | +32.50% | 4.06TCr | |
| -2.10% | +0.89% | -49.30% | -53.47% | 4.17TCr | |
| -0.72% | -7.96% | +49.53% | -27.69% | 2.94TCr | |
| +3.74% | -4.01% | +133.49% | -35.59% | 3.04TCr | |
| +1.07% | +1.42% | +72.47% | +90.95% | 2.37TCr | |
| +3.88% | +2.16% | +11.78% | +201.51% | 1.92TCr | |
| +1.13% | +1.04% | +65.41% | +137.02% | 1.71TCr | |
| Average | +0.06% | -1.35% | +43.83% | +82.76% | 3.27TCr | |
| Weighted average by Cap. | +0.30% | -1.30% | +36.43% | +55.33% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 70Cr 61Cr 56Cr 52Cr 99Cr 6.66TCr 100.49Cr 673.98Cr 264.2Cr 3.27TCr 261.9Cr 256.24Cr 11TCr | 91Cr 79Cr 73Cr 68Cr 128.42Cr 8.65TCr 130.57Cr 875.74Cr 343.29Cr 4.25TCr 340.3Cr 332.94Cr 15TCr |
| Net income | -3.85Cr -3.37Cr -3.11Cr -2.88Cr -5.46Cr -367.73Cr -5.55Cr -37Cr -15Cr -180.58Cr -14Cr -14Cr -625.51Cr | 16Cr 14Cr 13Cr 12Cr 22Cr 1.49TCr 23Cr 151.21Cr 59Cr 733.64Cr 59Cr 57Cr 2.54TCr |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/26/09 | $64.14 | -5.30% | 21,68,792 |
| 08/26/08 | $67.73 | -4.00% | 13,30,643 |
| 07/26/07 | $70.55 | +5.22% | 16,85,124 |
| 06/26/06 | $67.05 | +2.46% | 14,58,724 |
| 02/26/02 | $65.44 | +7.47% | 17,85,690 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TARS Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
